We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.60 | 0.22% | 269.98 | 267.00 | 280.00 | 271.68 | 265.72 | 265.72 | 2,436,961 | 05:00:03 |
From Apr 2022 to Apr 2024
By Chris Wack
LegoChem Biosciences Inc. said Friday that it has entered into a research collaboration and license agreement with Amgen Inc.
Under the deal, Amgen was granted rights to research, develop and commercialize antibody-drug conjugates directed against up to five targets selected by Amgen based on LegoChem's proprietary ConjuAll ADC technology.
LegoChem is eligible to receive up to $1.25 billion in payments and is also eligible for tiered royalties as a percentage of worldwide commercial sales by Amgen.
LegoChem said its clinical-stage ConjuAll ADC technology platform provides optimized site-specific conjugation, as well as cancer-selectively activating linker and payload technologies for ADCs.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 23, 2022 07:33 ET (12:33 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
